Fig. 2.

MSCs inhibit circulating C5 activation and ameliorate renal disease in lupus mice. (a-c) Plasma C3, C5a, and soluble C5b-9 (sC5b-9) in B6.lpr mice at 42 weeks (n = 4–6 per group). (d-e) The ratio of proteinuria to urinary creatinine, and plasma creatinine in B6.lpr mice during the course of treatments (n = 4–8 per group). (f) PAS staining of a representative glomerulus from three groups. Scale bar = 10 μm. (g) PathologIcal scores of glomerulonephritis in B6.lpr mice (n = 4–6 per group). (h) HE staining of a representative perivascular area from three groups. Scale bar = 10 μm. (i) The severity score for perivascular inflammatory cells infiltrated in kidneys of B6.lpr mice (n = 4–6 per group). *p < 0.05; **p < 0.01; ns, not significant. Values are the mean ± SEM.